title: Efalizumab-induced autoimmune pancytopenia.
abstract: Efalizumab is a recombinant, humanized monoclonal anti-CD11a antibody used for the treatment of moderate to severe plaque psoriasis. Immune-mediated thrombocytopenia and anaemia have previously been reported with this therapy. We describe the first case of immune-mediated pancytopenia in a patient treated with efalizumab. Close monitoring of all blood cell counts is warranted in light of this case.
authors.affiliation: Department of Dermatology, Saint Louis University School of Medicine, 1402 South Grand Blvd, MO 63104, USA.
authors.forename: W L
authors.initials: WL
authors.lastname: Tom
authors.forename: M D
authors.initials: MD
authors.lastname: Miller
authors.forename: M Y
authors.initials: MY
authors.lastname: Hurley
authors.forename: T
authors.initials: T
authors.lastname: Suneja
authors.forename: G
authors.initials: G
authors.lastname: Kudva
authors.forename: C L
authors.initials: CL
authors.lastname: Leonardi
authors.forename: J M
authors.initials: JM
authors.lastname: Obadiah
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000139:chemically induced*; D040881:CD11a Antigen / Q000276:immunology; D003879:Dermatologic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D010198:Pancytopenia / Q000139:chemically induced*; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D040881:CD11a Antigen; D003879:Dermatologic Agents; C472181:efalizumab